Anxiety Disorders - Pipeline Review, H2 2015 Is Released Anxiety Disorders - Pipeline Review, H2 2015 Summary Global Markets Direct s, Anxiety Disorders Pipeline Review, H2 2015, provides an overview of the Anxiety Disorders s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Anxiety Disorders and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects A review of the Anxiety Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Anxiety Disorders pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the 1
therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179096/anxiety-disorders-pipeline-review-h2-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179096/anxiety-disorders-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Anxiety Disorders Overview 11 Therapeutics Development 12 Pipeline Products for Anxiety Disorders - Overview 12 Pipeline Products for Anxiety Disorders - Comparative Analysis 13 Anxiety Disorders - Therapeutics under Development by Companies 14 Anxiety Disorders - Therapeutics under Investigation by Universities/Institutes 19 Anxiety Disorders - Pipeline Products Glance 20 Late Stage Products 20 Clinical Stage Products 21 Early Stage Products 22 Unknown Stage Products 23 Anxiety Disorders - Products under Development by Companies 24 Anxiety Disorders - Products under Investigation by Universities/Institutes 30 Anxiety Disorders - Companies Involved in Therapeutics Development 32 2
AbbVie Inc. 32 Ache Laboratorios Farmaceuticos S/A 33 Adamed Sp. z o.o. 34 Addex Therapeutics Ltd 35 Avineuro Pharmaceuticals, Inc. 36 Azevan Pharmaceuticals, Inc. 37 Bionomics Limited 38 Boehringer Ingelheim GmbH 39 C4X Discovery Limited 40 Catalyst Pharmaceutical Partners, Inc. 41 Edgemont Pharmaceuticals, LLC 42 Eisai Co., Ltd. 43 Eli Lilly and Company 44 F. Hoffmann-La Roche Ltd. 45 Gabather AB 46 GW Pharmaceuticals Plc 47 H. Lundbeck A/S 48 HolsboerMaschmeyer NeuroChemie GmbH 49 Humanetics Corporation 50 Intra-Cellular Therapies, Inc. 51 Johnson & Johnson 52 Marinus Pharmaceuticals, Inc. 53 Merz Pharma GmbH & Co. KgaA 54 3
MI.TO. Technology S.r.L. 55 Neuralstem, Inc. 56 Neurocrine Biosciences, Inc. 57 NeuroNascent, Inc. 58 Newron Pharmaceuticals S.p.A. 59 Nippon Chemiphar Co., Ltd. 60 Novartis AG 61 Omeros Corporation 62 Otsuka Holdings Co., Ltd. 63 Pherin Pharmaceuticals, Inc. 64 Polleo Pharma Limited 65 Protagenic Therapeutics Inc. 66 Rottapharm SpA 67 Sellas Inc. 68 Suda Ltd 69 Sumitomo Dainippon Pharma Co., Ltd. 70 Synchroneuron Inc. 71 Tonix Pharmaceuticals Holding Corp. 72 Trevena, Inc. 73 Vanda Pharmaceuticals Inc. 74 Anxiety Disorders - Therapeutics Assessment 75 Assessment by Monotherapy Products 75 Assessment by Target 76 Assessment by Mechanism of Action 80 4
Assessment by Route of Administration 84 Assessment by Molecule Type 86 Drug Profiles 88 18-MC - Drug Profile 88 acamprosate calcium SR - Drug Profile 89 ACH-36 - Drug Profile 91 ADN-2013 - Drug Profile 92 ADX-71441 - Drug Profile 93 ADX-71743 - Drug Profile 94 ADX-88178 - Drug Profile 95 alprazolam - Drug Profile 96 AM-3506 - Drug Profile 97 AVN-101 - Drug Profile 98 AVN-628 - Drug Profile 99 BCA-909 - Drug Profile 100 BHV-0223 - Drug Profile 101 BNC-210 - Drug Profile 103 brexpiprazole - Drug Profile 105 CPP-115 - Drug Profile 108 CR-5542 Series - Drug Profile 110 Read More http://www.idatainsights.com/reports-landing-page.php?id=179096/anxiety-disorderspipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both 5
primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
6